Successful New Treatment For Hodgkin's Lymphoma, Reduces Long-term Risks


  Friday 17 July 2009 - 00:59:21

New research led by Cindy Schwartz, MD, of Hasbro Children's Hospital has identified a new chemotherapy regimen for pediatric Hodgkin lymphoma (HL) patients. The new treatment enhances efficacy through dose-dense drug delivery while simultaneously reducing the long-term risks presented by high cumulative dose chemotherapy. Schwartz and the researchers of the Children's Oncology Group have published their findings in the journal Blood (posted in an online first edition).

The Children's Oncology Group's Hodgkin Lymphoma Committee, led by Schwartz, director of pediatric hematology/oncology at Hasbro Children's Hospital, recognized that treatment for HL in the United States was not being treated with the most modern treatment models, in large part because it was one of the first malignancies for which a curative chemotherapy regimen was developed.

Schwartz says, "For decades, the chemotherapy regimens known as MOPP and ABVD had been the standard treatment options for these patients. However, while they yielded excellent survival rates, they often resulted in long-term effects from toxicity, including infertility, second malignancy and cardiopulmonary toxicity. With the new treatment paradigm we've developed, in essence, we've been able to cure the cancer while reducing the risk of long-term effects on our patients."

The group designed a new chemotherapy treatment known as ABVE-PC, combining six different drugs into one "dose-dense" regimen that could limit the cumulative doses of each drug below the recognized thresholds known for resulting in long-term toxicity. Their goal was to reach a rapid early response (RER) in order to further reduce cumulative therapy and to thereby increase event-free survival (EFS). They also combined the chemotherapy treatment with low dose radiation following the completion of the ABVE-PC cycles.

The treatment developed by the researchers was unique given that its focus was on early response after nine weeks, measuring to detect primary chemosensitivity – a favorable response to chemotherapy, indicating that the therapy is working. This approach differs from the traditional evaluation of the response at the end of chemotherapy. Schwartz notes that this is important, because, "This early detection allows for a reduction in therapy for those who respond well to the dose-dense treatment, and therefore, individual response can be tailored for maximum efficacy."

Schwartz, who is also a professor of pediatrics at The Warren Alpert Medical School of Brown University, believes that the study represents a new treatment model for patients with HL. She states, "Our treatment paradigm for advanced HL relied on two treatment principles: dose density enhances therapeutic efficacy and rapid early response is evidence of chemosensitivity and can serve as a basis for reduction of therapy."

The researchers conducted a trial of 216 eligible patients under 22 years of age, with intermediate or high risk HL; there were 76 females and 140 males. The median time from initial treatment to completion of the third cycle was approximately 8.7 weeks, and completion of the fifth cycle was approximately 16 weeks. While the dose densities of the chemotherapy agents exceeded those of the most commonly used regimens, cumulative doses of the chemotherapy were significantly lower, particularly in those with RER. The study was conducted at Children's Oncology Group sites between 1997 and 2001.

Schwartz says, "The results of the study indicate that through this new chemotherapy treatment we have been able to effectively deliver dose-dense chemotherapy while reducing the cumulative exposure to our patients." There are other, more immediate outcomes of the new treatment paradigm that are also of note. Schwartz also adds, "Our patients truly appreciate the rapidity of treatment. Regimens traditionally used for intermediate and advanced disease require six to eight months of chemotherapy, instead of two to three and a half months. A major benefit of this new approach is that children and young adults are able to more quickly return to school and work."

Of the 216 eligible patients, 209 were able to be evaluated for response. Of those patients, 63 percent (132 patients) showed RER, and only two of the patients showed evidence of progressive disease. RER was achieved in 67 percent of intermediate HL patients and 61 percent of high risk HL patients. The five-year event-free survival for intermediate risk HL patients was 84 percent and 85 percent for high risk HL patients. Few relapses occurred beyond three years after enrollment.

Schwartz concludes, "We have successfully achieved five-year event free survival in 84 percent of the patients and overall survival in 95 percent of our patients with this dose-dense, early-response based treatment algorithm. Only nine weeks of chemotherapy were required in 63 percent of our patients. This study has shown conclusively that the new chemotherapeutic treatment of ABVE-PC simultaneously provides high efficacy and reduces the cumulative doses of chemotherapy and radiation. We believe this represents a significant advance in the treatment of HL."

Other researchers involved in the study with Schwartz include Louis S. Constine of the University of Rochester Medical Center in Rochester, NY; Doojduen Villaluna of Children's Oncology Group - Operations Center in Arcadia, CA; Wendy B. London of Children's Oncology Group – Statistics and Data Center, University of Florida in Gainesville, FL; Robert E. Hutchison of SUNY Upstate Medical University in Syracuse, NY; Richard Sposto of Children's Hospital Los Angeles in Los Angeles CA; Steven E. Lipshultz of University of Miami Miller School of Medicine in Miami, FL; Charles S. Turner of Wake Forest University School of Medicine in Winston-Salem, NC; Pedro A. deAlarcon of St. Jude Midwest Affiliate in Peoria, IL; and Allen Chauvenet of West Virginia University HSC in Charleston, WV.

http://www.sciencedaily.com/releases/2009/07/090713160521.htm




Headlines


»Ebola virus disease, West Africa – update
As of 18:00 on 16 April, the Ministry of Health (MOH) of Guinea has reported a cumulative total of ...
»Middle East respiratory syndrome coronavirus (MERS-CoV) – update
On 17 April 2014, the Ministries of Health of Malaysia and the United Arab Emirates (UAE) reported a ...
»Human infection with avian influenza A(H7N9) virus – update
On 15 April 2014, the National Health and Family Planning Commission (NHFPC) of China notified WHO o ...
»Middle East respiratory syndrome coronavirus (MERS-CoV) – update
On 13 and 14 April 2014 United Arab Emirates (UAE) reported a cluster of ten laboratory-confirmed ca ...


Date published: Fri, 18 Apr 2014 10:00:42 GMT
Details

»WHO issues its first hepatitis C treatment guidelines
9 April 2014 -- WHO has issued its first guidance for the treatment of hepatitis C, a chronic infect ...
»World Health Day 2014: Preventing vector-borne diseases
2 April 2014 -- More than half the world’s population is at risk from diseases such as malaria, deng ...
»7 million premature deaths annually linked to air pollution
25 March 2014 -- In new estimates released today, WHO reports that in 2012 around 7 million people d ...
»Progress in diagnosing multidrug-resistant tuberculosis
20 March 2014 -- Almost half a million people fell ill with multidrug-resistant tuberculosis (MDR-TB ...


Date published: Fri, 18 Apr 2014 10:01:19 GMT
Details

»First Trial of Targeted MRI vs Standard Prostate BiopsyFirst Trial of Targeted MRI vs Standard Prostate Biopsy
The results, presented at the European Association of Urology Congress, have 'completely radicalized ...
»ASCO Launches New Survivorship GuidelinesASCO Launches New Survivorship Guidelines
ASCO has launched the first 3 guidelines as part of a series that will cover all aspects of cancer s ...
»Simple Pocket Card Improves Estimation of Obstetric Blood LossSimple Pocket Card Improves Estimation of Obstetric Blood Loss
Visual estimation of obstetric blood loss was significantly improved after obstetric providers were ...
»New CDC/FDA Warning Against Unapproved Lyme Culture TestNew CDC/FDA Warning Against Unapproved Lyme Culture Test
Investigators from the CDC and FDA have issued a new warning about the use of unvalidated Lyme disea ...


Date published: not known
Details

»Diabetes Complications
Source: HealthDay - Related MedlinePlus Page: Diabetes Complications
»Misdiagnoses Common Among U.S. Outpatients
5 percent of adults are affected each year, data from several studies suggest Source: HealthDay Rel ...
»Diabetes Complication Rates Drop Among U.S. Adults
But at the same time, rates of diabetes have more than tripled, researchers report Source: HealthD ...
»Leeches Help Save Woman's Ear After Pit Bull Mauling
The 17-day treatment prevented blood vessel clogging that could threaten reconnection, surgeons say ...


Date published: Fri, 18 Apr 2014 00:16:53 EDT
Details

»Salmonella decline seen in food poisoning report
NEW YORK (AP) — The government's latest report card on food poisoning shows a dip in salmonella ...
»Obama: 8 million signed up for health care
WASHINGTON (AP) — Eight million people have signed up for health care through new insurance exchange ...
»Reservoir to be flushed because of urinating teen
PORTLAND, Ore. (AP) — The mix of 38 million gallons of treated water and one teen's urine has p ...
»USDA will require reporting of killer piglet virus PEDv
By Ros Krasny WASHINGTON (Reuters) - In an expected move, the U.S. Department of Agriculture on Frid ...


Date published: not known
Details